## Name of shareholder and personal identification number Name and personal identification number of representative as my/our representative, having the power to delegate his/her proxy, to attend and vote for me/us at the Annual General Meeting of Faron Pharmaceuticals Ltd to be held on the 5 April 2024 in Turku, Finland. Date: \_\_\_\_\_\_ Place: \_\_\_\_\_\_

## **Voting Instructions**

Shareholder's signature and name in block letters

**PROXY** 

Agenda items 6 to 8 cover proposals of the Board of Directors of Faron Pharmaceuticals Oy to the Extraordinary General Meeting in accordance with the notice of the meeting. To direct your proxy to vote with respect to the proposed resolution, please indicate the manner in which your proxy is to vote by checking (X) the appropriate box below. If you do not check any boxes below, your proxy will vote for the decision proposal contained in the notice to the Annual General Meeting published on 13 March 2024.

The option "For/Yes" means that the shareholder is in favor of approving the proposal. The option "Against/No" means that the shareholder objects to the acceptance of the proposal. "Abstain from voting" means giving an empty vote, in which case the shares are taken into account as shares represented in the handling of the agenda item, which has an impact with respect to resolutions requiring a qualified majority.

	Resolution item	For/Yes	Against/No	Abstain
7.	Adoption of the financial statements			
8.	Resolution on the use of the profit shown on the balance sheet and the payment of dividend			
9.	Resolution on the discharge of the members of the Board and the CEO of the Company from liability			
10.	Resolution on the remuneration of the members of the Board			
11.	Resolution on the number of members of the Board			
12.	Election of members of the Board			
13.	Resolution on the remuneration of the auditor			
14.	Election of the auditor			
15	Resolution on the establishment of Shareholder's Nomination Board			
16.	Authorising the Board to decide on the issuance of shares, options or other special rights entitling to shares			
17	Authorising the Board to resolve on the issuance of shares			